Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. (12th December 2018)

• Record Type: Journal Article
• Authors: Redondo, Alba M.; Valcárcel, David; González‐Rodríguez, Ana P.; Suárez‐Lledó, María; Bello, José L.; Canales, Miguel; Gayoso, Jorge; Colorado, Mercedes; Jarque, Isidro; del Campo, Raquel; Arranz, Reyes; Terol, María J.; Rifón, José J.; Rodríguez, María J.; Ramírez, María J; Castro, Nerea; Sánchez, Andrés; López‐Jiménez, Javier; Montes‐Moreno, Santiago; Briones, Javier; López, Aurelio; Palomera, Luis; López‐Guillermo, Armando; Caballero, Dolores; Martín, Alejandro
• Is Part Of: British journal of haematology. Volume 184:Number 5(2019)
• Page Start: 797
• Page End: 807
• Publication Date: 2018-12-12
• Subjects: bendamustine -- BEAM -- autologous stem‐cell transplantation -- aggressive lymphomas -- clinical trial; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15713
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem‐cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3‐year progression‐free survival (PFS). Sixty patients (median age 55 [28–71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9–72) and 14 (4–53) days to achieve neutrophil and platelet counts of >0.5 × 10 9 /l and >20 × 10 9 /l, respectively. Non‐relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow‐up of 67 (40–77) months, the estimated 3‐year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12–0.56]) and OS (RR, 0.40 [95% CI 0.17–0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies.